One quarter after AbbVie raised future sales estimates due to the successes of its immunology portfolio, the company again ...

When the board of Belgian biotech Galapagos asked Paul Stoffels to become CEO, he told them he was only interested in doing ...

Merck KGaA in talks to acquire SpringWorks Therapeutics for $47/share ($3.5B), gaining cancer drugs Ogsiveo and Gomekli. Deal ...

Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the ...

Caribou Biosciences is paring down its pipeline and cutting about a third of its workforce as cell and gene therapy companies ...

Merck CEO Rob Davis told investors on Thursday that he’s confident in the company’s ability to protect its top-selling ...

Only 66% of FDA-approved biosimilars launched, with Humira & Enbrel facing limited competition despite biosimilars priced ...

Merck, Bristol Myers Squibb, Sanofi and Roche — were eager to position themselves as fully prepared for whatever may come ...

The grow­ing drug dis­count pro­gram for low-in­come Amer­i­cans, known as the 340B pro­gram, has “trans­paren­cy and ...

San Diego biotech Halozyme is suing Merck over an injectable version of its blockbuster cancer drug, alleging that the new formulation will infringe on Halozyme's under-the-skin delivery patents.

Morgan Cheatham joins Breyer Capital as healthcare head, discusses AI virtual labs' potential in drug discovery.

Lotte Biologics, Ypsomed, PCI Pharma, Samsung Biologics, Catalent & Ferring share manufacturing updates: new ADC services, ...